Circulation Reports
Online ISSN : 2434-0790

This article has now been updated. Please use the final version.

N-Terminal Pro-B-Type Natriuretic Peptide Is a Predictor of Chronic Kidney Disease in an Asian General Population ― The Ohasama Study ―
Shingo NakayamaMichihiro SatohHirohito MetokiTakahisa MurakamiKei AsayamaAzusa HaraTakuo HiroseRyusuke InoueMegumi Tsubota-UtsugiMasahiro KikuyaTakefumi MoriAtsushi HozawaKoichi NodeYutaka ImaiTakayoshi Ohkubo
Author information
JOURNAL FREE ACCESS FULL-TEXT HTML Advance online publication
Supplementary material

Article ID: CR-19-0044

Details
Abstract

Background:N-terminal pro-B-type natriuretic peptide (NT-proBNP) is known to increase in heart failure patients. Given that no reports have described the association between NT-proBNP and chronic kidney disease (CKD) incidence in Asian populations, we investigated this association in the Japanese population.

Methods and Results:We followed up 867 participants without CKD from the general population of Ohasama, Japan. We defined CKD as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2and/or proteinuria. In accordance with previous studies, the participants were classified into 4 groups according to NT-proBNP level (<30.0, 30.0–54.9, 55.0–124.9, and ≥125.0 pg/mL). The Cox model was applied to assess adjusted hazard ratios (HR) for CKD incidence after full adjustment including baseline eGFR. Participant mean age was 59.1 years, and 587 (67.7%) were women. During the mean follow-up period of 9.7 years, 177 participants developed CKD. When the group with NT-proBNP <30.0 pg/mL was used as the reference, adjusted HR for CKD incidence in the 30.0–54.9, 55.0–124.9, and ≥125.0 pg/mL groups were 1.34 (95% CI: 0.90–2.01), 1.25 (95% CI: 0.81–1.92), and 1.83 (95% CI: 1.05–3.18), respectively.

Conclusions:NT-proBNP can be significantly predictive for CKD incidence in Asian populations.

Content from these authors
© 2019 THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
feedback
Top